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ORIGINAL ARTICLE
In patients with diabetes mellitus, insulin resis-
tance and plasma blood sugar can be improved
markedly by thiazolidinediones, which are ago-
nists of peroxisomal proliferator-activated receptor
(PPAR)-γ.1 Several non-hypoglycemic effects of this
type of drug have been reported, which poten-
tially are beneficial for cardiovascular protection.2,3
Thiazolidinediones can modify lipid profile,4,5 as
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Rosiglitazone Reduces Plasma Levels of
Inflammatory and Hemostatic Biomarkers
and Improves Global Endothelial Function in
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Background/Purpose: Thiazolidinediones have anti-atherothrombotic effects in diabetic patients. However,
the effects of rosiglitazone on inflammatory and hemostatic markers, as well as global endothelial function
in non-diabetic smokers are unknown.
Methods: Twenty-seven healthy male heavy smokers without metabolic syndrome were enrolled in this
double-blind, controlled study. Fourteen subjects received 4 mg/day rosiglitazone for 8 weeks (group R)
and 13 subjects received placebo (group C). Changes in the reflection index (RI) of β-agonist-induced 
endothelium-dependent vasodilatation by photoplethysmography and plasma biomarkers were measured
before and after treatment.
Results: Matrix metalloproteinase-9, fibrinogen, and high-sensitivity C-reactive protein were reduced sig-
nificantly in group R after treatment as compared with the baseline [84.1 (45.6–139.0) vs. 123.9 (58.4–141.8)
ng/mL, p = 0.03; 2914 (2400–3553) vs. 3220 (2542–3940) mg/L, p = 0.04; and 3.4 (2.2–5.1) vs. 5.5 (4.1–6.8)
mg/L, p = 0.009, respectively]. RI was improved markedly in group R as compared with the baseline [13.5
(4.2–65.1) vs. 2.5 (–10.6 to 9.3)%; p = 0.024]. These biomarkers and RI did not differ significantly in the
group C. There were no significant changes in fasting plasma glucose, insulin, homeostasis model assess-
ment index, and lipid profile in both groups R and group C.
Conclusion: Rosiglitazone significantly reduces plasma levels of inflammatory and hemostatic biomarkers,
and restores global endothelial dysfunction, independently from insulin sensitization, in healthy smokers.
[J Formos Med Assoc 2010;109(2):113–119]
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well as reduce plasminogen activator inhibitor-1,
fibrinogen, matrix metalloproteinase-9 (MMP-9),
and high-sensitivity C-reactive protein (hsCRP)
levels,5–7 and platelet aggregation.8 Several direct
vascular effects also have been reported, such as
improvement of endothelial dysfunction,5 reduc-
tion of blood pressure5 and arterial stiffness,9 in-
hibition of in-stent restenosis after percutaneous
coronary intervention,10 and restoration of im-
paired endothelial progenitor cell function.11 In
spite of much encouraging evidence, thiazolidine-
diones have been tested only in the metabolic
syndrome, including type 2 diabetes mellitus5,7
or hypertension.12–14 The most important issue is
whether these cardiovascular protective effects are
related to improved insulin sensitivity or are inde-
pendent from insulin sensitization by thiazolidine-
diones. If these cardiovascular protective effects are
independent from improved insulin sensitivity,
more patients without metabolic syndrome will
receive the benefits of thiazolidinedione treatment.
A lot of in vitro and in vivo evidence supports the
suggestion that PPAR-γ agonists provide anti-
inflammatory and fibrinolytic effects independent
from insulin sensitization.15–19 Therefore, efforts
must be made to investigate the cardiovascular pro-
tective effects in subjects at high risk for coronary
artery disease but not metabolic syndrome.
Cigarette consumption constitutes the most
important risk factor for coronary artery disease.
Compared with non-smokers, those who consume
20 or more cigarettes daily have a two- to three-
fold increase in coronary heart disease.20 We have
found that smoking is the most important tradi-
tional coronary risk factor in the young myocardial
infarction group.21,22 Smoking promotes athero-
thrombosis by several mechanisms, including im-
paired endothelium-dependent vasodilatation,23
increased inflammatory markers such as hsCRP,
soluble intercellular adhesion molecule-1 and fib-
rinogen,24,25 and enhanced platelet aggregation26
and MMP-9 activity.27 Accordingly, rosiglitazone
treatment may have the potential to modify the
cardiovascular risk profile in habitual smokers.
Therefore, we hypothesize that rosiglitazone can
modify the atherothrombosis profile in habitual
heavy smokers without diabetes mellitus or meta-
bolic syndrome, and that these beneficial effects




This was a prospective, double-blind, placebo-
controlled trial. This study enrolled 27 healthy
male volunteers (aged 20–45 years) with habit-
ual heavy smoking. The definition of habitual
heavy smoker was daily consumption of ≥ 20 
cigarettes for more than 5 years, or equivalent.
They continued tobacco smoking throughout
the whole study. Subjects were excluded if they
had the Asian-modified metabolic syndrome
[≥ 3 of the following: waist size ≥ 90 cm in men
or ≥ 80 cm in women; triglyceride ≥ 1.695 mmol/L
(150 mg/dL); high-density lipoprotein–cholesterol
< 1.036 mmol/L (40 mg/dL) in men or < 1.295
mmol/L (50 mg/dL) in women; systolic blood
pressure ≥ 130 mmHg or diastolic blood pressure
≥ 85 mmHg; fasting plasma glucose ≥ 5.5 mmol/L
(100 mg/dL)];13,28 liver dysfunction (transami-
nases ≥ 2 times upper limit of normal, history of
liver cirrhosis, or hepatoma); chronic renal fail-
ure; left ventricular dysfunction (ejection frac-
tion ≤ 50% by echocardiography) or active heart
failure (New York Heart Association function
class II or above); documented malignancy and
chronic inflammatory disease; clinical or electro-
cardiographic evidence of coronary artery dis-
ease; diabetes mellitus [if they had a fasting
blood glucose level ≥ 7 mmol/L (126 mg/dL) on
at least two separate occasions, or were being
controlled with either lifestyle modification or
hypoglycemic agents]; current use of rosiglita-
zone; or hypertension (elevated blood pressure
≥ 140/90 mmHg being measured on 3 occasions
or being treated with antihypertensive agents).
The whole study protocol was approved by the
Institutional Review Board of the National Cheng
Kung University Hospital. All study subjects gave
informed consent.
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Titration of the study drugs
During the run-in period of 1 week, eligible sub-
jects were screened. Blood biochemistry data, com-
plete blood cell and differential white blood cell
counts, and plasma marker levels were obtained.
Transthoracic echocardiography by standard pro-
cedure,29 and measurement of endothelial func-
tion by photoplethysmography after inhalation
of salbutamol, a β2-agonist, were performed. In
addition, blood pressure, body weight, and waist
size were also recorded. Body mass index was
calculated. The homeostasis model assessment
(HOMA) index30 was calculated as fasting plasma
insulin (μU/mL) × fasting glucose (mmol/L)/22.5.
Eligible volunteers were assigned randomly to
treatment with rosiglitazone 4 mg/day (group R,
n = 14) or placebo (group C, n = 13).
On the day after the end of the study period
(8 weeks), the aforementioned data were obtained
by the same procedures.
Blood sampling and measurement of 
serum and plasma markers
Blood samples were obtained from peripheral
veins in all study subjects at the run-in period
and the end of the study. The blood samples
were drawn into 5-mL EDTA or citrate glass tubes.
All biochemical samples were sent to the central
laboratory for immediate assay. Then, the others
were separated by centrifugation at 3000 rpm for
15 minutes and stored at –70°C until they were
assayed for substantial serum and plasma markers.
Plasma or serum concentrations of von Willebrand
factor (American Diagnostica, Stamford, CT, USA),
soluble P-selectin (R&D, Minneapolis, MN, USA),
MMP-9 (Oncogene, San Diego, CA, USA) and
hsCRP (American Diagnostica) were measured
using commercial ELISA kits according to the
manufacturers’ protocols.
Measurements of global endothelial function
by photoplethysmography after inhalation 
of a b2-agonist
Flow-mediated dilatation is one of the widely used
noninvasive methods to assess conduit artery en-
dothelial function. However, there are still some
controversies on its variation and reproducibility,
which potentially limits its use for follow-up mea-
surement in individual subjects.31–34 Inhalation
of a β2-adrenergic agonist induces endothelium-
dependent vasodilatation, which is known as
global endothelial function,34 and can be assessed
by recording the digital volume pulse from pho-
toplethysmography,35 with good reproducibility36
and correlation with acetylcholine injection.37
Commercial portable photoplethysmography ap-
paratus (Micro Medical Pulse Trace, Gillingham,
Kent, UK) was used for this study. Digital volume
pulse data were collected using a probe placed
on the index finger of the right hand, and in-
built software was used to provide a reflection
index (RI) that was related to the tone in the
small arteries. The RI was calculated as the height
of the inflection point after the first peak of the
digital volume pulse, and expressed as a percent-
age height of the first peak (Figure). After 20
minutes of supine rest, baseline measurements
were performed three times, 400 μg salbutamol
was inhaled through a spacer. After inhalation,
digital volume pulse was recorded every 5 min-
utes for 20 minutes. The change of RI (RI) was
expressed as the difference between the baseline
RI and that following inhalation.38
Statistical analysis
Distributions of continuous variables in both
groups are expressed as mean ± standard deviation
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b
Reflection index = a/b × 100%
a
Figure. Digital volume pulse (solid line) is formed by the
initial curve (coarse dotted line) and the following reflec-
tion curve (fine dotted line).
and skewed data are reported as median (inter-
quartile range). Comparisons between groups were
analyzed by using the Mann–Whitney U test.
Differences between baseline and post-treatment
values were analyzed by using the Wilcoxon
signed-rank test. A p value < 0.05 was regarded as
statistically significant. All statistical analyses were
performed using SPSS version 10.0 (SPSS Inc.,
Chicago, IL, USA).
Results
The background characteristics of the two groups
were similar and almost matched (Table). The
averaged duration of tobacco smoking was > 11
years in both groups.
All subjects completed the whole study. Com-
parison of changes in the background charac-
teristics, blood biochemistry data, and plasma
markers after treatment between the two groups
are shown in the Table. Although significant weight
gain and waist circumference increase were ob-
served in group R, the dose of rosiglitazone was
not reduced. Biochemistry checkup for safety
screening, including measurement of hemoglo-
bin, creatine phosphokinase, and transaminases,
did not show any significant change throughout
the study. Plasma levels of MMP-9, fibrinogen, and
hsCRP were reduced significantly after treatment
I.C. Chen, et al
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Table. Changes of parameters between participants assigned to rosiglitazone and placebo*
Parameters
Treatment group (n = 14) Placebo group (n = 13)
Before (baseline) After Before (baseline) After
Age (yr) 32.6 ± 5.8 30.8 ± 4.1
Smoking duration (yr) 11.3 ± 4.7 11.3 ± 5.7
Fasting plasma glucose (mmol/L) 4.5 ± 0.6 4.5 ± 0.6 4.6 ± 0.3 4.7 ± 0.5
Hemoglobin A1C (%) 5.5 ± 0.4 5.5 ± 0.4 5.5 ± 0.3 5.4 ± 0.2
Fasting insulin (μU/mL) 11.2 (8.4–13.9) 12.4 (8.5–15.0) 15.7 (7.9–23.2) 10.4 (6.6–22.0)
HOMA index 2.2 (1.8–2.7) 2.6 (1.8–3.0) 3.1 (1.6–4.8) 2.1 (1.3–4.9)
Weight (kg) 71 ± 9 72 ± 8† 68 ± 9 68 ± 9
Waist circumference (cm) 90 ± 7 93 ± 6† 89 ± 6 89 ± 8
Body mass index (kg/m2) 23.7 ± 2.7 24.0 ± 2.6 23.2 ± 2.9 23.6 ± 3.0
Blood pressure (mmHg)
Systolic 119 ± 8 115 ± 8 122 ± 10 122 ± 20
Diastolic 74 ± 11 74 ± 11 75 ± 12 73 ± 11
Total cholesterol (mmol/L) 4.8 ± 0.8 4.8 ± 1.0 4.8 ± 1.0 4.6 ± 1.0
Triglyceride (mmol/L) 1.1 (0.7–1.8) 1.4 (0.9–2.2) 1.2 (0.8–1.7) 1.3 (1.2–1.8)
HDL–cholesterol (mmol/L) 1.0 ± 0.2 1.0 ± 0.1 1.2 ± 0.4 1.3 ± 0.8
LDL–cholesterol (mmol/L) 3.1 ± 0.8 3.1 ± 0.9 3.0 ± 0.9 2.8 ± 0.9
MMP-9 (ng/mL) 123.9 (58.4–141.8) 84.1 (45.6–139.0)† 119.3 (36.8–146.3) 109.1 (51.5–138.7)
Fibrinogen (mg/L) 3220 (2542–3940) 2914 (2400–3553)† 3130 (2832–3435) 3348 (2818–3888)
Von Willebrand factor (mU/mL) 400.4 (360.0–492.1) 419.1 (382.0–530.5) 413.2 (363.0–520.9) 397.6 (346.0–522.6)
Soluble P-selectin (ng/mL) 92.6 (63.7–104.1) 89.8 (54.5–138.7) 74.5 (56.1–111.9) 102.9 (72.9–135.7)
hsCRP (mg/L) 5.5 (4.1–6.8) 3.4 (2.2–5.1)‡ 5.5 (4.0–6.6) 5.4 (3.2–5.5)
RI (%) 2.5 (–10.6 to 9.3) 13.5 (4.2–65.1)† 7.7 (0–20.3) 13.3 (–5.5 to 48.3)
*Data presented as mean ± standard deviation or median (interquartile range), multiplication factors for converting conventional units to SI units: glucose
(mg/dL × 0.055 = mmol/L), cholesterol (mg/dL × 0.0259 = mmol/L), and triglyceride (mg/dL × 0.0113 = mmol/L); †p < 0.05 vs. baseline; ‡p < 0.01 vs. baseline.
HOMA = homeostasis model assessment; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MMP-9 = matrix metalloproteinase-9; hsCRP =
high-sensitivity C-reactive protein; RI = changes of the reflection index.
compared with the baseline levels in group R [84.1
(45.6–139.0) vs. 123.9 (58.4–141.8) ng/mL, p =
0.03; 2914 (2400–3553) vs. 3220 (2542–3940)
mg/L, p = 0.04; and 3.4 (2.2–5.1) vs. 5.5 (4.1–6.8)
mg/L, p = 0.009, respectively]; however, these
markers did not differ significantly in group C.
There were no significant changes in plasma levels
of fasting plasma glucose, insulin, hemoglobin
A1C, HOMA index, lipid profiles, von Willebrand
factor, and P-selectin.
Changes in parameters with regard to vascu-
lar endothelial function are shown in the Table.
RI by photoplethysmography was improved
markedly in group R [13.5 (4.2–65.1) vs. 2.5 
(−10.6 to 9.3)%; p = 0.024] but did not differ 
significantly in group C.
Discussion
This randomized, double-blind, placebo-
controlled study investigated the effect of rosigli-
tazone on cardiovascular profile modification in
habitual heavy smokers without diabetes mel-
litus or metabolic syndrome. We demonstrated
that rosiglitazone significantly reduced plasma
level of hsCRP, fibrinogen, and MMP-9, and re-
stored global endothelial function, independ-
ently from insulin sensitization. To the best of
our knowledge, these findings have not been re-
ported previously.
Almost all of the previous studies of thiazo-
lidinediones on non-traditional markers of car-
diovascular disease and endothelial function have
been performed in patients with type 2 diabetes5,7
or metabolic syndrome.12–14 Furthermore, the
beneficial effects were much or less associated
with insulin sensitization.5,7,12–14 Only one small
study, without a placebo control, has revealed a
rapid beneficial effect of rosiglitazone on endothe-
lial function and biomarkers in volunteers with-
out diabetes or metabolic syndrome.39 Our study
suggested that rosiglitazone directly influenced
global endothelial function independently from
its effect on glycemic control and lipid modula-
tion, which agreed with a previous study.39 We
conducted the present study in healthy individuals
without diabetes mellitus or metabolic syndrome,
and we did not find any significant changes in
glucose or insulin level, lipid profile or HOMA
index. As a result of the relatively short duration
of treatment and the healthy individuals enrolled,
the HOMA index did not change significantly with
treatment, in accordance with a previous study.39
Despite improved insulin sensitivity being the
mainstay of management in metabolic syndrome
and type 2 diabetes mellitus,40 a substantial
body of in vitro and in vivo evidence suggests that
PPAR-γ agonists exert anti-inflammatory and fib-
rinolytic effects independent from insulin sensi-
tization.15–19 Our previous genetic study also has
revealed that the C161T homozygous mutation
is associated significantly with the occurrence of
premature myocardial infarction, independent
from the presence of diabetes mellitus.41 Previ-
ous studies also have shown that rosiglitazone
reduces serum inflammatory biomarkers of ath-
erosclerosis and endothelial dysfunction as early
as 2 weeks after initiation of glitazone treatment,
whereas these agents exhibit their maximal met-
abolic action after 8–12 weeks.7,39 Taken together,
these results show a direct anti-inflammatory ef-
fect of glitazones in the vasculature independent
from insulin sensitization.39
It has been shown previously that PPAR-γ
protein expression is increased in monocytes/
macrophages from healthy smokers, which is a
possible direct effect of nicotine.42 Furthermore,
our previous study has shown that tobacco smok-
ing and C161T polymorphism of the PPAR-g
gene synergistically influence the occurrence of
premature myocardial infarction.41 Accordingly,
PPAR-g could serve as a novel target for myocardial
infarction in habitual smokers.
The reduction of serum levels of some bio-
markers of inflammation, and improvement of
global endothelial function with short-term treat-
ment with rosiglitazone in our study, highlights
the potential cardiovascular benefit of glitazone
treatment in subjects without diabetes mellitus
or metabolic syndrome. In vitro evidence has re-
vealed that rosiglitazone can reduce inflammation
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through nuclear factor-κB and STAT-1 (signal
transducers and activators of transcription-1) re-
pression15 and oxidative stress inhibition.16 Fur-
thermore, attenuation of inflammation as well as
oxidative stress could contribute to improved 
endothelial function.
Although our participants did not meet the cri-
teria for metabolic syndrome,13,28 we cannot ex-
clude the possibility of insulin resistance among
these study subjects. Nevertheless, the significant
cardiovascular effects exerted by rosiglitazone
were robust, even though there was no obvious
improvement of insulin sensitization during this
short-term treatment. In our population, rosigli-
tazone had no significant effect on changes in
adhesion molecules, being similar to the previ-
ous study performed by Marx and his colleagues.7
Given the small number of participants and short-
term treatment, we cannot exclude the possibility
that these inflammatory markers could be reduced
significantly in a large-scale trial. The effects of
thiazolidinediones on cardiovascular morbidity
and mortality in patients with type 2 diabetes
mellitus are controversial.43,44 Nevertheless, fur-
ther study is warranted to investigate the anti-
atherothrombotic effect of rosiglitazone in primary
prevention of coronary artery disease in other
high-risk groups, or secondary prevention of 
pre-existing coronary heart disease or myocardial 
infarction, in patients without diabetes mellitus.
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